New cancer drug enters first human testing
NCT ID NCT07346846
Summary
This is the first human study of an experimental cancer drug called BGM-2121. Researchers will test it in 35 adults with advanced solid tumors who have already tried standard treatments. The main goals are to find the safest dose and see how the body handles the drug, while also checking for early signs that it might help control cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cheng Kung University Hospital
Tainan, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Taiwan University Hospital
Taipei, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Taipei Veterans General Hospital
Taipei, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.